Summit Therapeutics Inc. (SMMT)
- Previous Close
24.65 - Open
24.65 - Bid 23.69 x 3500
- Ask 24.10 x 3500
- Day's Range
23.45 - 25.34 - 52 Week Range
2.10 - 36.91 - Volume
2,530,125 - Avg. Volume
4,035,898 - Market Cap (intraday)
17.794B - Beta (5Y Monthly) -0.95
- PE Ratio (TTM)
-- - EPS (TTM)
-0.34 - Earnings Date Aug 4, 2025 - Aug 8, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
37.41
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.
www.smmttx.comRecent News: SMMT
View More
Performance Overview: SMMT
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SMMT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SMMT
View MoreValuation Measures
Market Cap
17.79B
Enterprise Value
17.44B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
51.68
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-52.50%
Return on Equity (ttm)
-123.93%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-240.76M
Diluted EPS (ttm)
-0.34
Balance Sheet and Cash Flow
Total Cash (mrq)
361.32M
Total Debt/Equity (mrq)
1.87%
Levered Free Cash Flow (ttm)
-104.8M